ArticleWorld journal of surgery2008
Long-term outcome of reoperations for medullary thyroid carcinoma.
Article in World journal of surgery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Thyroid : official journal of the American Thyroid Association · 2015Guideline
- The Management of Medullary Thyroid Cancer: A Review.Annals of surgical oncology · 2026Review
- Multifocality as a marker of aggressiveness in medullary thyroid carcinoma: a retrospective cohort analysis of lymph node metastasis and recurrence.The oncologist · 2026Article
- The value ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.World journal of surgical oncology · 2024Article
- The Role ofMolecular imaging and radionuclide therapy · 2023Article
- Management of lymph nodes in medullary thyroid carcinoma: A review.Annals of medicine and surgery (2012) · 2022Review
- Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.Endocrine · 2022Review
- Medullary Thyroid Cancer: 60 Years of Gradual Understanding.Annals of surgical oncology · 2022Article
- Recurrent medullary thyroid carcinoma treated with percutaneous ultrasound-guided radiofrequency ablation: A case report.World journal of clinical cases · 2021Article
- Review
- Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.Indian journal of surgical oncology · 2018Article
- Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.JAMA surgery · 2018Article
- Surgical management of medullary thyroid carcinoma.Updates in surgery · 2017Review
- Targeted Therapy for Medullary Thyroid Cancer: A Review.Frontiers in oncology · 2017Review
- Recent Updates on the Management of Medullary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2016Review
- Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.Annals of surgical oncology · 2015Article
- Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.The Journal of clinical endocrinology and metabolism · 2013Review
- Treatment of advanced medullary thyroid cancer.Thyroid research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMost patients with medullary thyroid carcinoma (MTC) have persistent disease after primary surgery, as evidenced by calcitonin elevation. Previous reports showed that reoperation on selected patients yields immediate calcitonin normalization in one-third of patients. Long-term follow-up data are needed to assess the outcome in such patients. This report aims to provide 8- to 10-year follow-up on reoperations for persistent or recurrent MTC.
methodsAn Internal Review Board (IRB) approved database on patients treated for MTC has been prospectively maintained. This database was reviewed to report follow-up data on calcitonin levels and survival.
resultsBetween 1992 and 2006, 148 patients underwent reoperations for recurrent or persistent MTC (55 patients had 59 reoperations for palliation, and 93 patients had 105 reoperations for cure). Of the 93 patients operated on for cure (44 with hereditary MTC, 49 with the sporadic form), 8-10-year follow-up data were available on 56. Four patients died of disease (4.3% of 93). Two died of unrelated causes, and were excluded from calcitonin outcome analysis. Fourteen patients of 54 (26.0%) have unstimulated calcitonin levels of <10 pg/ml at 8-10 years. Eleven additional patients (20.4%) have levels<100 pg/ml. None of these 25 patients (46.4%) have radiologic recurrence.
conclusionsPrevious reports demonstrated the low morbidity of reoperation for MTC in experienced hands, and success was determined by lowering of calcitonin levels. Follow-up data demonstrate that at least one third of such patients have long-term eradication of their disease following reoperation, as evidenced by biochemical and imaging studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.